• Hebrew SeniorLife: “Class of Alzheimer’s Drug Presents Unique Challenge for Patients With Cardiovascular Disease, Says JAMA Article: Authors advocate for additional research to improve decision-making before initiating lecanemab” (March 28, 2024)
• Akston Biosciences: “Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility” (March 11, 2024)
• Hebrew SeniorLife: “Study Finds Higher Risk for Fracture From Falls in Men Than in Women Previous falls should be integrated in FRAX to increase predictive accuracy of future falls” (March 8, 2024)
• Akston Biosciences: “Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility” (Feb. 26, 2024)
• Prota Therapeutics: “Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments” (Jan. 16, 2024)
• Birnbach Communications: “Birnbach Communications Issues Key Media, Business and Tech Predictions for 2024” (Jan. 9, 2024)